Low dosage may be behind low efficacy of CureVac vaccine: Study leader

Berlin: The low dosage might be a key reason why CureVac's COVID-19 vaccine reported disappointing efficacy in a pivotal late-stage trial, the scientist leading the study of the shot said on Thursday.

The German biotech's vaccine proved only 47% effective in an initial trial, far lower than those of rivals BioNTech/Pfizer and Moderna, which are also based on mRNA technology and had efficacy rates well above 90%. Peter Kremsner from the University Hospital in Tuebingen which is running the trial told Reuters the low efficacy is "very likely due to the dose".